Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.76 USD | +1.94% | +5.51% | +28.50% |
20/06 | TD Cowen Initiates Vericel at Buy With $55 Price Target | MT |
14/06 | Vericel Insider Sold Shares Worth $1,526,350, According to a Recent SEC Filing | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 381.33 times its estimated earnings per share for the ongoing year.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+28.50% | 2.22B | C | ||
+2.97% | 94.74B | A- | ||
-4.08% | 37.28B | A- | ||
-13.26% | 32.68B | B- | ||
+74.02% | 27.72B | A | ||
-11.58% | 16.19B | C | ||
-1.66% | 13.88B | B- | ||
-11.67% | 11.58B | D+ | ||
+190.36% | 10.92B | D | ||
-52.61% | 9.54B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- VCEL Stock
- Ratings Vericel Corporation